IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Therapy-Related Myelodysplastic Syndrome
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Therapy-Related Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clofarabine M.D. Anderson Cancer Center | Phase 3 | BB |
Orca-T Orca Biosystems, Inc. | Phase 3 | B |
FILGRASTIM-SNDZ M.D. Anderson Cancer Center | Phase 2 | CCC |
Erwinia L-Asparaginase Andrew E. Place, MD | Phase 1 | CC |
Calaspargase Pegol Andrew E. Place, MD | Phase 1 | CC |
Solu-Cortef Andrew E. Place, MD | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →